Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minocycline and doxycycline are not beneficial in a model of Huntington's disease.

Annals of neurology - 1 Aug 2003

Smith Donna L, Woodman Benjamin, Mahal Amarbirpal, Sathasivam Kirupa, Ghazi-Noori Shabnam, Lowden Philip A S, Bates Gillian P, Hockly Emma

Abstract excerpt

Huntington's Disease (HD) is an inherited neurological disorder causing movement impairment, personality changes, dementia, and premature death, for which there is currently no effective therapy. The modified tetracycline antibiotic, minocycline, has been reported to ameliorate the disease phenotype in the R6/2 mouse model of HD. Because the tetracyclines have also been reported to inhibit aggregation in other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Doxycycline
Share to Huntingtin Protein

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Huntington Disease

Share to Hyperglycemia

Share to Minocycline

Share to Organ Culture Techniques

Share to Postural Balance

Share to Tetracycline

Source

Identifiers

PMID: 12891671
DOI: 10.1002/ana.10614

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minocycline and doxycycline are not beneficial in a model of Huntington's disease.PMID 12891671Read ↗

Lack of minocycline efficiency in genetic models of Huntington's disease.Semantic proximity Read ↗

Minocycline in phenotypic models of Huntington's disease.Semantic proximity Read ↗

Minocycline for Huntington’s disease: An open label studySemantic proximity Read ↗

Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease.Semantic proximity Read ↗

Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.Semantic proximity Read ↗

Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfoldingSemantic proximity Read ↗

Doxycycline: An essential tool for Alzheimer’s diseaseSemantic proximity Read ↗

Minocycline Attenuates Neuronal Cell Death and Improves Cognitive Impairment in Alzheimer's Disease ModelsSemantic proximity Read ↗

Minocycline inhibits cell death and decreases mutant Huntingtin aggregation by targeting Apaf-1.Semantic proximity Read ↗

Treatment with Tau fibrils impact Huntington's disease-related phenotypes in cell and mouse models.Semantic proximity Read ↗

Can minocycline prevent the onset of Alzheimer's disease?Semantic proximity Read ↗

Testing the Therapeutic Potential of Doxycycline in a Drosophila melanogaster Model of Alzheimer DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.